According to the New York Times, pharmaceutical company Novartis is facing a criminal investigation for alleged false claims made in connection to their best-selling drug Diovan.
Japan’s Health Ministry has called for a criminal investigation into Novartis, accusing the Swiss pharmaceutical giant of distributing pamphlets to health care professionals suggesting that their hypertension drug was also effective in preventing strokes and other heart conditions.
The study cited a number of other studies conducted at Japanese universities, but the universities announced last year that Novartis employees were involved in the trials and that all resulting data was suspect.
While Novartis has acknowledged the involvement of their employees in the studies, the company denies any knowledge of data being manipulated or mishandled.
Diovan is an angiotensis receptor blocker that was approved in2005 for the treatment of high blood pressure and heart failure. Since its release, Novartis has attempted to expand the drug’s uses, claiming it can treat stroke, diabetic nephropathy and can prolong life after heart attack.
Diovan has been linked to serious adverse events including:
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or pharmaceuticals, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.